Reata Pharmaceuticals Inc... (RETA)
172.36
0.04 (0.02%)
At close: Sep 25, 2023, 8:00 PM
0.02% (1D)
| Bid | n/a |
| Market Cap | 6.57B |
| Revenue (ttm) | 24.39M |
| Net Income (ttm) | -80.06M |
| EPS (ttm) | -2.6 |
| PE Ratio (ttm) | -66.29230769230769 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 1,909,215 |
| Avg. Volume (20D) | 954,093 |
| Open | 172.34 |
| Previous Close | 172.32 |
| Day's Range | 172.32 - 172.46 |
| 52-Week Range | 21.83 - 172.46 |
| Beta | 1.42 |
About RETA
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated ...
Industry Biotechnology
Sector Healthcare
IPO Date May 26, 2016
Employees 321
Stock Exchange NASDAQ
Ticker Symbol RETA
Website https://www.reatapharma.com